Acorda Therapeutics, Inc. (ACOR)
| Market Cap | 60.03M |
| Revenue (ttm) | 165.30M |
| Net Income (ttm) | 49.11M |
| Shares Out | 7.95M |
| EPS (ttm) | 6.13 |
| PE Ratio | 0.99 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 25 |
| Last Price | $6.05 |
| Previous Close | $6.33 |
| Change ($) | -0.28 |
| Change (%) | -4.42% |
| Day's Open | 6.35 |
| Day's Range | 6.02 - 6.45 |
| Day's Volume | 200,555 |
| 52-Week Range | 2.53 - 9.84 |
Acorda Therapeutics (ACOR) has been struggling lately, but the selling pressure may be coming to an end soon.
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Departure of Chief, Business Operations
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent
During Acorda's (ACOR) upcoming Q4 earnings call, investor focus will be on the sales uptake of its Parkinson's disease drug, Inbrija.
Acorda (ACOR) inks an agreement to sell its Inbrija manufacturing operations in Chelsea for $80 million to Catalent. The company also announces a corporate restructuring plan to save costs.
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a definitive agreement to sell its INBRIJA manufacturing operations in Chelsea...
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Heal...
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present during the January 11th -14th H.C. ...
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-6 reverse stock split of its outstanding and autho...
Acorda (ACOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors need to pay close attention to Acorda (ACOR) stock based on the movements in the options market lately.
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q3 2020 Results - Earnings Call Transcript
Acorda (ACOR) delivered earnings and revenue surprises of 23.33% and 80.64%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Acorda Therapeutics (NASDAQ:ACOR) increased 8.33% after the company reported Q3 results. Quarterly Results Earnings per share rose 50.00% over the past year to ($0.23), which beat th...
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ:ACOR) today reported its financial results for the third quarter ended September 30, 2020. “We are encouraged by the 24% incre...
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its third quarter 2020 update and financial results on Tues...
Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Acorda Therapeutics (ACOR) stock based on the movements in the options market lately.
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2020 Results - Earnings Call Transcript
Acorda (ACOR) delivered earnings and revenue surprises of 23.91% and 27.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Acorda Therapeutics (NASDAQ:ACOR) moved higher by 0.66% after the company reported Q2 results.
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc.
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc.
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc.
Investors need to pay close attention to Acorda Therapeutics (ACOR) stock based on the movements in the options market lately.
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock?
Acorda's (ACOR) earnings and revenues fall shy of estimates in the first quarter of 2020. The company withdraws revenue view for its Parkinson's disease drug Inbrija due to the ongoing COVID-1...
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2020 Results - Earnings Call Transcript
Acorda (ACOR) delivered earnings and revenue surprises of -45.71% and -28.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
During Acorda's (ACOR) upcoming Q1 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug, Inbrija.
Acorda Therapeutics (ACOR) closed the most recent trading day at $1.06, making no change from the previous trading session.
Acorda Therapeutics (ACOR) closed the most recent trading day at $0.93, moving -0.11% from the previous trading session.
Acorda (ACOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock?
Acorda (ACOR) beat earnings and revenue estimates in the fourth quarter of 2019.
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2019 Results - Earnings Call Transcript
Acorda (ACOR) delivered earnings and revenue surprises of 63.41% and 11.88%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Acorda (ACOR) reports lower-than-expected loss in the fourth quarter while revenues beat estimates.
During Acorda's (ACOR) Q4 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug Inbrija.
Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Acorda (ACOR) stock based on the movements in the options market lately.
Acorda Therapeutics (ACOR) shares rose nearly 6% in the last trading session, amid huge volumes.
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock?
Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States, which is hurting the company's top line of late. Parkinson's disease drug Inbrija seems an ideal replace...
Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q3 2019 Results - Earnings Call Transcript
Acorda (ACOR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
During Acorda's (ACOR) third-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.
Acorda (ACOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Acceleron Pharma's (XLRN) pipeline candidate, ACE-083, fails to translate muscle volume growth into improvements in functional tests in FSHD patients. Acceleron discontinues development.
About ACOR
Acorda Therapeutics, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment... [Read more...]
| Industry Biotechnology | IPO Date Feb 10, 2006 |
| CEO Ron Cohen | Employees 344 |
| Stock Exchange NASDAQ | Ticker Symbol ACOR |
Analyst Forecasts
According to 3 analysts, the average rating for ACOR stock is "Buy." The 12-month stock price forecast is 17.00, which is an increase of 180.99% from the latest price.